Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
SANJAY RAM · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2024 · $208,392 — PROJECT SUMMARY/ABSTRACT About 87 million new cases of gonorrhea occur worldwide annually. In 2020, 677,769 cases were reported to the CDC, a 111% increase in annual incidence since the historic low in 2009. Neisseria gonorrhoeae (Ng) has become resistant to almost every antibiotic in clinical use. …
Jordan Green · JOHNS HOPKINS UNIVERSITY · 2024 · $538,330 — PROJECT SUMMARY Cancer vaccines have significantly advanced cancer immunotherapy; and recent successes of mRNA vaccines have raised prospect of generating potent anti-tumor response by specifically delivering mRNAs encoding tumor-associated antigens to antigen presenting cells (APCs). However, APC a…
Olivia Selfridge Rissland · FEDERATION OF AMER SOC FOR EXPER BIOLOGY · 2024 · $5,000 — PROJECT SUMMARY A counterbalance to RNA synthesis, RNA degradation is critical for regulating gene expression. The understanding that RNA degradation is critical for gene expression traces back to 1959 when Pardee, Jacob and Monod demonstrated in a historical paper that there had to be an unstable i…
Karl Munger · TUFTS UNIVERSITY BOSTON · 2024 · $418,426 — Despite the currently available effective prophylactic vaccines, human papilloma virus infections remain the most common cause of venereal disease. Human papilloma virus-associated diseases are particularly prevalent in medically underserved segments of the population. Despite decades of research, t…
John H Adams · UNIVERSITY OF SOUTH FLORIDA · 2024 · $965,047 — Project Summary/Abstract Plasmodium vivax is the second leading cause of malaria and the most prevalent cause of malaria outside of Africa. The estimated cost of the global burden of vivax malaria is $1.4 - $4 billion per year and more people live at risk worldwide from P. vivax than P. falciparum. …
Ian J Mohr · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2024 · $436,140 — 7. PROJECT SUMMARY / ABSTRACT Regulation of gene expression at the level of translation allows cells and organisms to respond swiftly to physiological stress and changing environments. Indeed, differential translation of capped, polyadenylated mRNAs by eukaryotic ribosomes plays a critical role in b…
Brian Frederick Pickering · CHIMERNA THERAPEUTICS INC. · 2024 · $297,608 — SUMMARY: Circular RNAs (circRNAs) are a novel class of RNAs that hold immense potential as therapeutics due to their unique cellular functions. However, the challenges associated with their synthesis and purification have impeded their research and development. Chimerna proposes to develop a platfor…
Xiangfei Han · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $49,225 — ABSTRACT Protein replacement therapy has been a cornerstone in treating genetic diseases (e.g., hemophilia) with loss or reduction of the function of a particular protein, by using recombinant proteins or recombinant engineered proteins. However, most protein therapeutics have short circulation live…
Vitaly V. Ganusov · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2024 · $634,089 — Research Summary Tuberculosis (TB), a disease caused by the bacteria Mycobacterium tuberculosis (Mtb), remains a major infec- tious disease of humans in the world. After the initial local infection of one site in the lung Mtb somehow dissem- inates in the lung and often spreads beyond the lung. In f…
Guido Ferrari · DUKE UNIVERSITY · 2024 · $5,733,658 — ABSTRACT The ultimate goal of the proposed studies is to contribute to ending the HIV/AIDS epidemic. It has been four decades since the start of the HIV/AIDS epidemic and a protective vaccine or functional cure has been elusive. In 2020, there was an estimated 37.6 million people living with HIV. D…
Xiang-Jun Lu · COLUMBIA UNIV NEW YORK MORNINGSIDE · 2024 · $522,974 — X3DNA-DSSR is a unique resource that excels in structural bioinformatics of nucleic acids. The proposed resource builds upon the features and large user base of 3DNA and DSSR enabled by the grant R01GM096889 on “Continued Development and Maintenance of the 3DNA Suite of Programs” (June 2011 to Augus…
Duane R. Wesemann · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $686,383 — Project Summary Antibodies specific for pathogenic threats can provide immediate protection from infectious disease but longevity of an antibody responses after vaccination or infection can be highly variable. Responses induced by some live vaccines can persist for a lifetime, whereas protein-based …
Zhongchao Zhao · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2024 · $130,350 — PROJECT SUMMARY/ABSTRACT Ovarian cancer is the most lethal gynecologic malignancy for women; standard of care surgery and chemotherapy treatment can provide a short period of remission but cannot eradicate the disease and prevent recurrence. Cancer immunotherapy has shown great potential in treating…
Julia Meghan Davis-Porada · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $50,974 — PROJECT SUMMARY Vaccines save lives, and the rapid development of novel vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was a triumph for the medical community. While the rapid deployment of these vaccines has undoubtedly attenuated the severe morbidity and mortality in…
Marian L Kohut · IOWA STATE UNIVERSITY · 2024 · $191,250 — PROJECT SUMMARY / ABSTRACT Vaccination is an effective public health measure, yet host factors including advanced age, sex, obesity, physical or mental health status may influence vaccine efficacy. Adjuvants improve immunogenicity to vaccination but often result in greater side effects. As an alter…
Steven M Lipkin · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $115,661 — Admin Core: Project Summary/Abstract A significant overall goal of CAP-IT is to identify and validate immunologically targeted agents for precision prevention of individuals with increased cancer risk. The CAP-IT Center for RNA Immunoprevention (CRI) Administrative Core (AC) mission is to ensure tha…
Steven M Lipkin · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $433,293 — PROJECT SUMMARY Computerized chest tomography (CT) lung cancer screening programs have increased the detection of premalignant non-solid (NS) nodules that harbor preinvasive or minimally invasive adenocarcinoma. Given that NS nodules can progress to invasive adenocarcinoma (solid nodules), interce…
Benjamin L Miller · UNIVERSITY OF ROCHESTER · 2024 · $369,041 — Abstract The field of Osteoimmunology was established in 2005 to understand how bone influences immune and hematopoietic cells, as well as how hematopoietic and immune cells influence bone, in clinical conditions like osteomyelitis. However, several critical research tools and rigorously validated p…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $511,558 — The Administrative Core A, led by Dr. Richard Wyatt, will administer support for Projects 1 and 2 and Cores B and C, under the umbrella of this new HIVRAD proposal. This Core will coordinate an administrative partnership plan to maintain good communications within the HIVRAD working group and rele…
DAVID MCCORMICK · IIT RESEARCH INSTITUTE · 2024 · $1,020,618 — PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER…